RT Journal Article
SR Electronic
T1 ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4937
OP 4946
DO 10.21873/anticanres.14497
VO 40
IS 9
A1 KATHRIN FLESCHUTZ
A1 LISA WALTER
A1 RUMO LEISTNER
A1 LUCIE HEINZERLING
YR 2020
UL http://ar.iiarjournals.org/content/40/9/4937.abstract
AB Background/Aim: ALK inhibitors like Crizotinib, Ceritinib and Alectinib are targeted therapies used in patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). Since in this tumor entity radiotherapy is employed sequentially or concomitantly, potential synergistic effects were investigated, which may support the hypothesis of induced radiosensitization by using ALK inhibitors. Materials and Methods: Two cell lines expressing wild-type (WT) or echinoderm microtubule-associated protein-like 4 (EML4)-ALK were treated with ALK inhibitors, followed by irradiation. Cell survival, cell death, cell cycle and phosphorylation of H2A histone family, member X (H2AX) were examined. Results: Combined treatment with ALK-inhibitors plus 10 Gy-irradiation led to effects similar to those of sole radiotherapy, but was more effective than sole drug treatment. Conclusion: There is no clear evidence of sensitization to radiation by treating EML4-ALK mutated cells with ALK inhibitors.